PKC-412, under developmenet by Novartis, is an inhibitor of VEGFR, PDGFR and multiple protein kinase Cs. Protein kinase C (PKC) is a family of serine-threonine protein kinases that are involved in signal transduction pathways that regulate cellular growth factor, proliferation, and apoptosis.
For manufacturer information on PKC-412 link here.
Phase I/II clinical trials of the combination of imatinib mesylate and PKC-412 for the treatment of imatinib mesylate-resistant GIST were carried out. The trial protocols utilized a combination of imatinib mesylate plus PKC-412, as many of the tumor cells may still be under control or slowed by imatinib. A favorable strong drug-drug synergism between imatinib mesylate and PKC-412 provide rationale for this ongoing trial. The trial is no longer recruiting.
Oregon Health Science University
Dr. Charles Blanke, principal investigator
Trial information or enrollment, contact:
Clinical Trials Coordinator:
Phone: 503 494-1081
To read an interview with Dr. Charles Blanke, MD, FACP regarding this trial click here.
Charité Campus in Berlin
Trial information or enrollment contact:
Clinical Trials coordinator: Phone: 49 30 94 17-1203
Dr. Peter Reichardt presented at ASCO 2005 about this trial. You can read his abstract and view his slides through the ASCO site.
PubMed articles referencing preclinical use of PKC-412 with GIST cells can be viewed at this link.
Additional PubMed citations discussing PKC-412 actions against other cancers can be viewed at this link.